ABSTRACT: LBA17
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection...
The University of Texas MD Anderson Cancer Center will celebrate the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual tribute on Sept. 23. The hour-long event will be available for viewing starting at 4 p.m. CT at mdanderson.org/FreireichTribute.
Freireich died Feb. 1 at the age of 93. He is recognized as a founding father of modern clinical cancer research and for breaking medical barriers and pioneered the...
Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations...
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was...
The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
HOUSTON ― The University of Texas MD Anderson Cancer Center is joining forces with Houston Dynamo FC to raise awareness of childhood cancer...
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement...